Posted on

Avance Clinical 庆祝GlobalReady成功　超过40家生物技术客户进入计划

San Francisco, Jan 12, 2023 - (亚太商讯 via SEAPRWire.com) - 超过 40 家生物技术客户现在正在利用 Avance Clinical 的 GlobalReady 计划，该计划提供简化的临床开发，从澳大利亚的早期阶段扩展到北美的后期阶段。所有这些都由一个 CRO 和跨越两个地区的专门团队完成。Avance Clinical 在 2023 年生物技术展示会上宣布了这一消息，该团队将通过 PartnershipOne 召开会议。Avance Clinical 首席执行官 Yvonne Lungershausen 表示：“鉴于 GlobalReady 的早期成功采用，我们预计我们一半以上的生物技术客户将在未来六个月内加入该计划。”GlobalReady 生物技术客户主要是来自美国和亚洲的生物技术公司，预计未来几个月来自欧洲的客户数量会增加。Avance Clinical在过去3年连续被Frost & Sullivan评为“CRO最佳实践奖”。首席执行官 Yvonne Lungershausen 说：“这些生物技术客户已经从我们向北美和 GlobalReady 的扩张中受益。 这种 GlobalReady 模型旨在扩大生物技术公司的投资，使他们能够以更少的支出实现更大的临床开发里程碑，所有这些都以 FDA 接受的数据为保证。GlobalReady 为我们在澳大利亚和新西兰进行早期研究的生物技术客户提供了进入美国继续其临床开发计划的无缝旅程，同时保留了同样高质量的 CRO，从而减少了时间和成本，并提供了 FDA 认可的高质量数据。此外，在澳大利亚，43.5% 的临床支出回扣极具吸引力，为我们的客户提供了利用我们北美运营专业知识和团队的机会，同时保持在澳大利亚的服务以最大限度地发挥回扣潜力。我们经常指出，目前有超过 280 项全球 III 期试验在澳大利亚进行了 I 期研究，这再次证明了澳大利亚数据在 FDA 和其他主要监管机构中的可接受性。”这种无缝的 GlobalReady 之旅旨在取得成功，生物技术公司可以：- 利用澳大利亚早期临床试验环境（没有IND 和 43.5% 的退税）- 为后期过渡或扩展到北美 - 无需更改 CRO（保留研究知识和流程/团队）- 在两个地区无缝实施全球剂量递增和剂量扩展试验- 利用显着的速度和成本优势- 确保数据质量——可转移且易于被 FDA 和其他监管机构接受首席执行官Yvonne谈到，“我们有着非常高的回头业务率，这足以证明我们的技术以及以客户为本的临床专家可以在快节奏和强竞争的环境中脱颖而出，满足我们客户的需求。”根据 Frost & Sullivan 对公司 CRO 奖的独立分析师审查的一部分：“Avance Clinical 仍然是值得信赖的合作伙伴，在 CRO 行业提供整体最佳服务方面赢得了声誉。凭借其强劲的整体表现，Avance Clinical 在合同研究组织行业赢得了 Frost & Sullivan 颁发的 2022 年亚太客户价值领导奖。”更多信息：- 了解澳大利亚临床试验优势 https://www.avancecro.com/the-australian-advantage/- 了解 GlobalReady 模式 这里 https://www.avancecro.com/avance-clinical-north-america-operations/ - 了解更多Avance Clinical执行临床试验的优势: enquiries@avancecro.com 关于Avance ClinicalAvance Clinical是澳大利亚和新西兰地区最大的一站式CRO公司。我们为客户提供高质量的临床研究服务以及符合国际标准的临床研究数据。我们的客户主要是处于早期研发阶段的生物科技公司，他们需要快捷灵活的临床研究服务。Frost & Sullivan奖Avance Clinical作为一家具有24年历史的CRO公司在过去两年连续被评为Frost & Sullivan亚太地区市场领袖 。临床前到临床一期和二期Avance Clinical经验丰富的ClinicReady团队可提供精准的临床前服务。澳大利亚政府的研发税务补助政策，让我们可以更经济，精准并灵活的帮助客户完成临床一期和二期的项目。客户有机会享受43.5%的政府现金补助，同时快速的监管审批政策使其能更早更快的开展临床研究。我们的解决方案以及客户为本，灵活多变，经手的临床研究覆盖超过105个适应症。我们的数据质量被国际监管机构广泛认可，包括美国FDA以及欧洲EMA。技术我们使用的系统多元化并且功能丰富，有最高效的以及客户所信任的执行力。Medidata、Oracle和Medrio都是我们的系统长期供应商。媒体联系方式：Avance ClinicalKate Thompsonmedia@avancecro.com Copyright 2023 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Celebrates GlobalReady Success as more than 40 Biotech Clients Enter Program

SAN FRANCISCO, CA, Jan 11, 2023 - (ACN Newswire via SEAPRWire.com) - More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program which delivers streamlined clinical development from early phase in Australia expanding to sites in North America for later phases. All with the one CRO and dedicated teams across both regions.Avance Clinical made the announcement at Biotech Showcase 2023 where the team is taking meetings via PartnershipOne. "Given this successful early adoption of GlobalReady we are expecting more than half of our biotech clients to join the program within the next six months, said Avance Clinical CEO Yvonne Lungershausen.GlobalReady biotech clients are primarily biotechs from the US and Asia, with an increasing number expected from Europe over the next few months.Avance Clinical is the leading Australian-based biotech CRO with US operations, which has been recognized by Frost & Sullivan for the past 3 years with the prestigious CRO Leadership Award.CEO Yvonne Lungershausen said: "These biotech clients are already benefiting from our expansion into North America and GlobalReady. The GlobalReady model is designed to extend biotechs' investments so they can achieve greater clinical development milestones with reduced spend, all with the assurance of FDA-accepted data. GlobalReady gives our biotech clients conducting their early phase studies in Australia and New Zealand a seamless journey into the US to continue their clinical development programs, retaining the same high-quality CRO, which reduces time and cost and delivers quality FDA-accepted data. In addition, the attractive 43.5% rebate on clinical spend in Australia, offers our clients the opportunity to utilize our North American operations expertise and team, whilst maintaining services in Australia to maximize their rebate potential. We often point to the fact that there are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which again demonstrates Australian data acceptability with the FDA and other major regulatory authorities."This seamless GlobalReady journey is designed for success whereby biotechs can:- Take advantage of the Australian early-phase clinical trial landscape (No IND and 43.5% tax rebate)- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)- Seamlessly operationalize global dose-escalation and dose-expansion trials across the two regions- Harness significant speed and cost advantages- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities"We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biotech clients need for clinical success," commented Yvonne Lungershausen.According to Frost & Sullivan as part of the independent analyst review of the company for the CRO Award: "Avance Clinical remains a trusted partner, earning a reputation for delivering the overall best in the CRO industry. With its strong overall performance, Avance Clinical earns Frost & Sullivan's 2022 Asia-Pacific Customer Value Leadership Award in the contract research organization industry."Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Learn about the GlobalReady model here https://www.avancecro.com/avance-clinical-north-america-operations/- For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.comAbout Avance ClinicalAvance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. https://www.avancecro.com/Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.Media Contact: Avance ClinicalKate Thompsonmedia@avancecro.com Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical赞助全球Scrip奖项的中国生物制药奖

ADELAIDE, AUS & SAN DIEGO, Oct 27, 2022 - (亚太商讯 via SEAPRWire.com) - Avance Clinical 将出席下个月在伦敦举办的全球生物科技Scrip奖项颁奖典礼，并且赞助颁发中国生物制药奖。Avance Clinical对进入中国生物制药奖最终候选名单的公司表示祝贺，它们分别是：- 安泰康赛- 百济神州- 腾盛博药- 三叶草生物制药- 云顶新耀Avance Clinical的首席执行官Yvonne Lungershausen女士将在2022年11月30日举行的颁奖典礼上亲自颁发该奖项，全球商务拓展总监 Liahna Toy女士也将参加该典礼。据悉，将有超过400家生物科技公司参加此次颁奖典礼。关于中国生物制药奖， Yvonne Lungershausen发表了自己的想法：“我们有超过20%的客户来自中国，亲眼看到中国生物制药的在全球制药创新舞台上大放异彩，赞助该奖项也是为了表达我们对中国生物制药公司的敬意。目前，Avance Clinical的很多中国客户都计划获得FDA的监管审批。我们已经正式启动北美本地运营模式，为客户提供全新的GlobalReady服务。 与我们合作，既满足了他们在澳洲提前开启早期临床试验的时间战略需求，也满足了其后期研发进入美国市场，获取更多中心以及患者资源的地域战略需求，同时做到研发周期以及研发地区的无缝衔接。Avance Clinical在澳大利亚的运营模式可以帮助客户获得43.5%的税务补助以及满足全球临床监管要求的临床数据。GlobalReady服务将满足客户在研发后期获得美国FDA审批的需求。 我们规模的迅速扩张以及高“回头客”率已经很好的证明了我们有能力帮助客户实现临床研发的最终成功。”今年是Scrip奖成立的第十八个年头，此次颁奖典礼让全球制药行业的领导者们齐聚一堂，庆祝整个行业的最佳创新以及个人和公司获得的成就。典礼上将公布15个不同奖项的最终获奖单位以及个人。Avance Clinical是一家拥有北美运营模式的澳大利亚本土CRO公司，致力于为本地以及国际生物制药公司提供符合国际标准的临床研究服务，服务范围横跨各个临床研究阶段。同时，Avance Clinical也是一家被澳大利亚基因科技监管办公室（OGTR）认证的基因科技CRO，这使其有资格进行疫苗以及基因修饰生物体相关的临床研究。 首席执行官Yvonne谈到，“我们有着非常高的回头业务率，这足以证明我们的技术以及以客户为本的临床专家可以在快节奏和强竞争的环境中脱颖而出，满足我们客户的需求。”Avance Clinical在过去两年连续被Frost & Sullivan评为“CRO最佳实践奖”。更多信息：- 了解澳大利亚临床试验优势https://www.avancecro.com/the-australian-advantage/ - 了解Avance Clinical在细胞和基因疗法领域的经验www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/ - 了解更多Avance Clinical执行临床试验的优势: enquiries@avancecro.com 关于Avance ClinicalAvance Clinical是澳大利亚和新西兰地区最大的一站式CRO公司。我们为客户提供高质量的临床研究服务以及符合国际标准的临床研究数据。我们的客户主要是处于早期研发阶段的生物科技公司，他们需要快捷灵活的临床研究服务。 Frost & Sullivan奖Avance Clinical作为一家具有24年历史的CRO公司在过去两年连续被评为Frost & Sullivan亚太地区市场领袖 。临床前到临床一期和二期Avance Clinical经验丰富的ClinicReady团队可提供精准的临床前服务。澳大利亚政府的研发税务补助政策，让我们可以更经济，精准并灵活的帮助客户完成临床一期和二期的项目。客户有机会享受43.5%的政府现金补助，同时快速的监管审批政策使其能更早更快的开展临床研究。我们的解决方案以及客户为本，灵活多变，经手的临床研究覆盖超过105个适应症。我们的数据质量被国际监管机构广泛认可，包括美国FDA以及欧洲EMA。技术我们使用的系统多元化并且功能丰富，有最高效的以及客户所信任的执行力。Medidata、Oracle和Medrio都是我们的系统长期供应商。媒体联系方式： Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Wins International Health Award for Biotech CRO Services

SYDNEY, AU, Sep 28, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the leading Australian-based biotech CRO with US operations has won the South Australian Premier's Export Awards - International Health category. The award recognises excellence in clinical services exports.Avance Clinical CEO Yvonne LungershausenThe Premier of South Australia Peter Malinauskas, and Minister for Trade and Investment Nick Champion, presented the Premier's Export Awards to Avance Clinical CEO Yvonne Lungershausen at the awards industry event today. This follows Avance Clinical's selection as finalist for the Informa Pharma Intelligence Awards 2022 Best Contract Research Organization in APAC. Avance Clinical, which is backed by global private equity firm The Riverside Company, recently acquired a leading CRO in North America to expand services and offer their biotech clients US sites for later phase studies. CEO Yvonne Lungershausen said Avance Clinical is now the leading Australian-based biotech CRO with US operations. "We are honoured to be selected for the award. We are a major employer with more than 220 staff and we bring significant biotech clinical research business into South Australia and Australia. Clinical research is a high-value export that keeps our medical, research, and biopharma sectors at the forefront of international knowledge and innovation. The majority of our clients are from North America, the EU, and Asia so we really are an internationally-focused organisation. Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients and we are very proud of our growth and success in recent years."The company provides global regulatory standard clinical research services across all phases to the international biopharma industry. Avance Clinical is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) for vaccines and GMO therapies clinical trials."We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Read more about Avance Clinical's cell and gene therapy capabilities here www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/- For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.comAbout Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for more than 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical 宣布收购北美 CRO扩大生物技术的后期服务

SYDNEY, AU, Sep 6, 2022 - (亚太商讯 via SEAPRWire.com) - 澳大利亚生物技术 CRO 公司 Avance Clinical 已通过收购 CRO 合作伙伴公司 C3 Research Associates 扩展到北美，以使生物技术客户能够从早期研究到后期研究的无缝旅程。 Avance Clinical 的全球扩张计划得到了私募股权集团 Riverside Company 的支持。观看视频 https://www.avancecro.com/avance-clinical-north-america-operations/Avance Clinical 是澳大利亚和新西兰最大和最成熟的全方位服务 CRO，在 FDA 和所有其他主要监管机构的数据接受方面有着良好的记录。Avance Clinical 澳大利亚、新西兰和北美的联合运营为生物技术公司提供了独特的 GlobalReady 药物开发模式。Avance Clinical 的首席执行官 Yvonne Lungershausen 说：“近年来，Avance Clinical 一直与 C3 Research Associates 合作，他们有着相似的文化，并专注于客户服务和临床卓越。这种牢固的关系使 C3 Research Associates 成为 Avance Clinical 向北美扩张计划的自然收购选择。尽职调查过程耗时 6 个多月，我们很高兴现在欢迎我们的美国团队为我们的客户提供 GlobalReady 模型。此次收购使我们在澳大利亚和新西兰进行早期研究的生物技术客户可以无缝进入美国，继续他们的临床开发计划，保留相同的高质量 CRO，从而减少时间和成本，并提供 FDA 接受的高质量数据。这种 GlobalReady 模型旨在扩大生物技术公司的投资，使他们能够以更少的支出实现更大的临床开发里程碑，所有这些都以 FDA 接受的数据为保证。此外，在澳大利亚，43.5% 的临床支出回扣极具吸引力，为我们的客户提供了利用我们北美运营专业知识和团队的机会，同时保持在澳大利亚的服务以最大限度地发挥回扣潜力。我们经常指出，目前有超过 280 项全球 III 期试验在澳大利亚进行了 I 期研究，这再次证明了澳大利亚数据在 FDA 和其他主要监管机构中的可接受性。我们将对我们的美国业务进行重大投资，包括将团队扩大到 120 多人，并利用他们在广泛的治疗领域（特别是肿瘤学）的深厚行业经验。客户可以放心，世界一流的最佳实践技术、系统和流程将被整合到所有地区。”这种无缝的 GlobalReady 之旅旨在取得成功，生物技术公司可以：- 利用澳大利亚早期临床试验环境（没有IND 和 43.5% 的退税）- 为后期过渡或扩展到北美 - 无需更改 CRO（保留研究知识和流程/团队）- 在两个地区无缝实施全球剂量递增和剂量扩展试验- 利用显着的速度和成本优势- 确保数据质量——可转移且易于被 FDA 和其他监管机构接受Avance Clinical 团队提供卓越的研究批准和成功率，这可归功于其深厚的科学专业知识、先进的数据技术、对澳大利亚、新西兰和北美监管环境的了解，以及与网站和 KOL 的广泛关系。同时，Avance Clinical也是一家被澳大利亚基因科技监管办公室（OGTR）认证的基因科技CRO，这使其有资格进行疫苗以及基因修饰生物体相关的临床研究。我们有着非常高的回头业务率，这足以证明我们的技术以及以客户为本的临床专家可以在快节奏和强竞争的环境中脱颖而出，满足我们客户的需求。Avance Clinical在过去两年连续被Frost & Sullivan评为“CRO最佳实践奖 ”。了解澳大利亚临床试验优势: https://www.avancecro.com/the-australian-advantage/在这里与北美领导团队会面: https://www.avancecro.com/avance-clinical-north-america-operations/了解更多Avance Clinical执行临床试验的优势: https://www.avancecro.com/contact-us/关于Avance ClinicalAvance Clinical是澳大利亚和新西兰地区最大的一站式CRO公司。我们为客户提供高质量的临床研究服务以及符合国际标准的临床研究数据。我们的客户主要是处于早期研发阶段的生物科技公司，他们需要快捷灵活的临床研究服务。Frost & Sullivan奖Avance Clinical作为一家具有24年历史的CRO公司在过去两年连续被评为Frost & Sullivan亚太地区市场领袖 。临床前到临床一期和二期Avance Clinical经验丰富的ClinicReady团队可提供精准的临床前服务。澳大利亚政府的研发税务补助政策，让我们可以更经济，精准并灵活的帮助客户完成临床一期和二期的项目。客户有机会享受43.5%的政府现金补助，同时快速的监管审批政策使其能更早更快的开展临床研究。我们的解决方案以及客户为本，灵活多变，经手的临床研究覆盖超过110个适应症。我们的数据质量被国际监管机构广泛认可，包括美国FDA以及欧洲EMA。技术我们使用的系统多元化并且功能丰富，有最高效的以及客户所信任的执行力。Medidata、Oracle、IBM Watson和Medrio都是我们的系统长期供应商。媒体联系方式：Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs

SYDNEY, AU, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates, enabling biotech clients a seamless journey from early phase to later phase studies. Avance Clinical has backing from private equity group Riverside Company for their global expansion program.Watch the video here: https://www.avancecro.com/avance-clinical-north-america-operations/Avance Clinical is the largest and most established full-service Australian and New Zealand CRO with a proven track-record of data acceptance by the FDA and all other major regulatory bodies.The combined Avance Clinical Australia, New Zealand, and North American operations deliver a unique GlobalReady drug development model for biotechs.Avance Clinical's CEO Yvonne Lungershausen said: "Avance Clinical has been working with C3 Research Associates in recent years and they share a similar culture and focus on customer service and clinical excellence. This strong relationship made C3 Research Associates a natural acquisition choice for Avance Clinical's expansion plans into North America. The due diligence process has taken more than 6 months and we are excited to now welcome our US team and offer the GlobalReady model for our clients. "This acquisition gives our biotech clients conducting their early phase studies in Australia and New Zealand a seamless journey into the US to continue their clinical development programs, retaining the same high-quality CRO, which reduces time and cost and delivers quality FDA-accepted data. This GlobalReady model is designed to extend biotechs' investments so they can achieve greater clinical development milestones with reduced spend, all with the assurance of FDA accepted data. "In addition, the attractive 43.5% rebate on clinical spend in Australia, offers our clients the opportunity to utilize our North American operations expertise and team, whilst maintaining services in Australia to maximise their rebate potential. "We often point to the fact that there are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which again demonstrates Australian data acceptability with the FDA and other major regulatory authorities."We will be making significant investments in our US operations including growing the team to more than 120 people and leveraging their deep industry experience across a broad range of therapeutic areas, in particular oncology.Clients can be assured the world-class best practice technologies, systems and processes will be integrated across all regions."This seamless GlobalReady journey is designed for success whereby biotechs can:- Take advantage of the Australian early phase clinical trial landscape (No IND and 43.5% tax rebate)- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)- Seamlessly operationalise global dose-escalation and dose-expansion trials across the two regions- Harness significant speed and cost advantages- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities The Avance Clinical team offers exceptional study approval and success rates which can be attributed to its deep scientific expertise, advanced data technologies, knowledge of the Australian, New Zealand and North American regulatory environment, and its extensive relationships with sites and KOLs.The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which allows it to manage pre-clinical and clinical trials for vaccines and GMO therapies.Avance Clinical's has achieved high growth and industry-leading repeat business rates with its focus on gold standard technology paired with solution-orientated clinical experts. This is the mix that biopharma clients clearly require in this fast-moving, competitive and high-stakes sector.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Learn about the Australian Advantage here: https://www.avancecro.com/the-australian-advantage/Meet the North American leadership team here: https://www.avancecro.com/avance-clinical-north-america-operations/For more information about the benefits of running your next study with Avance Clinical contact us https://www.avancecro.com/contact-us/About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO with operations across Australia, New Zealand and North America delivering quality clinical trials with globally accepted data for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.Pre-clinical to Later Phase Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to later phase clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.State-of-the-art TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance 临床赞助商在 2022 年 Informa Pharma Intelligence Awards 中获得年度生物技术公司奖

ADELAIDE, AUS, Aug 30, 2022 - (亚太商讯 via SEAPRWire.com) - Avance Clinical 是澳大利亚领先的国际生物技术 CRO，在 2022 年 Informa Pharma Intelligence Awards 上赞助了两个奖项 - 年度私有和上市生物技术公司，并且也是亚太地区最佳合同研究组织的决赛入围者。年度生物技术公司奖表彰的成就包括“将业务从早期阶段转变为更成熟的公司、签署变革性交易、将其第一个或主要新产品推向市场，或筹集大量新资金”。首席执行官 Yvonne Lungershausen 和首席战略官 Ben Edwards 将出席颁奖晚会，并于下周在日本为生物技术客户举办餐桌。由全球私募股权公司 The Riverside Company 支持的 Avance Clinical 正在制定区域和国际扩展计划。与 Avance Clinical 一起，亚太地区最佳合同研究组织的决赛入围者是：- Calyx- CMIC Group- EPS- ICON- Parexel- Syneos HealthAvance Clinical 的首席执行官 Yvonne Lungershausen 说：“Avance Clinical 非常高兴能够赞助这些生物技术奖项。 我们是国际生物技术公司的 CRO，与 Informa Pharma Intelligence 的合作表明了我们对生物技术行业的持续支持和投资。”年度生物技术公司的决赛入围者 - 私有公司- ARTham Therapeutics- Chordia Therapeutics- Cuorips- Heartseed- Prism BioLab- Rebirthel- ReboRNA Biosciences- TMS年度生物技术公司的决赛入围者——上市公司- NanoCarrier- Rakuten Medical (Rakuten Group Inc.’s equity accounted affiliate)- Sosei Heptares- Stella Pharma- StemCell InstituteAvance Clinical的首席执行官Yvonne Lungershausen表示，“Avance Clinical能够进入到如此有声望的一个奖项的最终候选名单，我们感到非常荣幸。这是Informa Pharma Intelligence的评委们对以客户为本的Avance Clinical团队的肯定，也是对我们提供的CRO服务质量的肯定。Avance Clinical在全球久负盛名，因为我们能为生物科技公司提供灵活的解决方案，加速临床研发进度。我们对于公司近年来在亚太地区的发展以及取得的成就感到非常自豪。”根据Informa Pharma Intelligence的标准：该奖项的设立是为了表彰在日本以及亚洲其他地区包括澳大利亚的一站式CRO服务公司。评委们会考量CRO公司的服务质量，客户关系及受试者招募的创新度。该奖项的评定标准是基于2021年各个CRO公司取得的成就。核心评审标准包括：- CRO公司的独特优势和能力- CRO公司如何超出申办方预期的完成相关任务- CRO公司在受试者招募战略方面的创新度- CRO公司如何提高业务质量，如：数据质量，时间线及透明度- CRO公司在统一数据收集和汇报方面的流程更多信息请访问: https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022Avance Clinical是一家澳大利亚本土CRO公司，致力于为本地以及国际生物制药公司提供符合国际标准的临床研究服务，服务范围横跨各个临床研究阶段。同时，Avance Clinical也是一家被澳大利亚基因科技监管办公室（OGTR）认证的基因科技CRO，这使其有资格进行疫苗以及基因修饰生物体相关的临床研究。首席执行官Yvonne谈到，“我们有着非常高的回头业务率，这足以证明我们的技术以及以客户为本的临床专家可以在快节奏和强竞争的环境中脱颖而出，满足我们客户的需求。”Avance Clinical在过去两年连续被Frost & Sullivan评为“CRO最佳实践奖 ”。更多信息：- 了解澳大利亚临床试验优势https://www.avancecro.com/the-australian-advantage/- 了解Avance Clinical在细胞和基因疗法领域的经验 www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/- 了解更多Avance Clinical执行临床试验的优势: enquiries@avancecro.com关于Avance ClinicalAvance Clinical是澳大利亚和新西兰地区最大的一站式CRO公司。我们为客户提供高质量的临床研究服务以及符合国际标准的临床研究数据。我们的客户主要是处于早期研发阶段的生物科技公司，他们需要快捷灵活的临床研究服务。Frost & Sullivan奖Avance Clinical作为一家具有24年历史的CRO公司在过去两年连续被评为Frost & Sullivan亚太地区市场领袖 。临床前到临床一期和二期Avance Clinical经验丰富的ClinicReady团队可提供精准的临床前服务。澳大利亚政府的研发税务补助政策，让我们可以更经济，精准并灵活的帮助客户完成临床一期和二期的项目。客户有机会享受43.5%的政府现金补助，同时快速的监管审批政策使其能更早更快的开展临床研究。我们的解决方案以及客户为本，灵活多变，经手的临床研究覆盖超过110个适应症。我们的数据质量被国际监管机构广泛认可，包括美国FDA以及欧洲EMA。技术我们使用的系统多元化并且功能丰富，有最高效的以及客户所信任的执行力。Medidata、Oracle、IBM Watson和Medrio都是我们的系统长期供应商。媒体联系方式：Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Sponsors Biotech Company of the Year Awards at Informa Pharma Intelligence Awards 2022

ADELAIDE, AUS, Aug 29, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the leading Australian CRO for international biotechs, is sponsoring two awards - Biotech Company of the Year Private and Public - at the Informa Pharma Intelligence Awards 2022 and is also a finalist for the Best Contract Research Organization in APAC.The Biotech Company of the Year awards recognize achievements including "moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds".CEO Yvonne Lungershausen and Chief Strategy Officer Ben Edwards are attending the awards night and hosting a table for biotech clients in Japan next week. Avance Clinical, which is backed by global private equity firm The Riverside Company, is in the process of regional and international expansion plans.Along with Avance Clinical, the finalists for the Best Contract Research Organization APAC are:- Calyx- CMIC Group- EPS- ICON- Parexel- Syneos HealthAvance Clinical's CEO Yvonne Lungershausen said: "Avance Clinical is extremely pleased to be sponsoring these biotech awards. We are the CRO for international biotechs and this collaboration with Informa Pharma Intelligence shows our ongoing support and investment for the biotech industry."The finalists for Biotech Company of the Year - Private:- ARTham Therapeutics- Chordia Therapeutics- Cuorips- Heartseed- Prism BioLab- Rebirthel- ReboRNA Biosciences- TMSThe finalists for Biotech Company of the Year - Public:- NanoCarrier- Rakuten Medical (Rakuten Group Inc.'s equity accounted affiliate)- Sosei Heptares- Stella Pharma- StemCell Institute"In addition, we are extremely honored to be selected as a finalist for the prestigious award Best Contract Research Organization in APAC. It is a credit to our customer-focused team for delivering world-leading CRO services for biotechs which has been recognized by the Informa Pharma Intelligence award judges. Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients. We are very proud of our growth and success in recent years."According to Informa Pharma Intelligence, this Award is to recognize CROs that provide full or specialist services to their clients and which have an office in either in Japan or the Asia region including Australia. Judging considers the quality of services and relationships built with clients and pays particular attention to the innovative patient recruitment strategies the CRO has brought to the table. The award is based on achievements in the 2021 calendar year.Core areas judged include:- The particular capabilities and strengths the CRO offers- How the company has delivered results that exceed sponsor expectations- Innovations in patient recruitment strategy has the CRO brought to its partner- How it has improved its performance, for example, in its quality of data, timelines and transparency- The steps the company is taking towards streamlining data collection and reportingTo find out more please visit: https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry. The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies."We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Read more about Avance Clinical's cell and gene therapy capabilities here www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/ - For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.com About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for more than 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical进入Informa Pharma Intelligence 2022年亚太地区最佳CRO最终候选名单

ADELAIDE, AUS, Apr 19, 2022 - (亚太商讯 via SEAPRWire.com) - Avance Clinical是澳大利亚本地最大的CRO，致力于协助世界各地的生物科技及制药公司完成早期临床研究。今年Avance Clinical进入了Informa Pharma Intelligence 2022年亚太地区最佳CRO最终候选名单。 近年来，Avance Clinical 发展迅速，最近在墨尔本和悉尼都开设了新办公室以支持其日益壮大的临床运营团队。该奖项的最终获得者将于2022年9月1日公布。目前的候选企业包括：- Avance Clinical- Calyx- CMIC Group- EPS- ICON- Parexel- Syneos HealthAvance Clinical的首席执行官Yvonne Lungershausen表示，“Avance Clinical能够进入到如此有声望的一个奖项的最终候选名单，我们感到非常荣幸。这是Informa Pharma Intelligence的评委们对以客户为本的Avance Clinical团队的肯定，也是对我们提供的CRO服务质量的肯定。Avance Clinical在全球久负盛名，因为我们能为生物科技公司提供灵活的解决方案，加速临床研发进度。我们对于公司近年来在亚太地区的发展以及取得的成就感到非常自豪。” 根据Informa Pharma Intelligence的标准：该奖项的设立是为了表彰在日本以及亚洲其他地区包括澳大利亚的一站式CRO服务公司。 评委们会考量CRO公司的服务质量，客户关系及受试者招募的创新度。该奖项的评定标准是基于2021年各个CRO公司取得的成就。核心评审标准包括：- CRO公司的独特优势和能力- CRO公司如何超出申办方预期的完成相关任务- CRO公司在受试者招募战略方面的创新度- CRO公司如何提高业务质量，如：数据质量，时间线及透明度- CRO公司在统一数据收集和汇报方面的流程更多信息请访问: https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022Avance Clinical最近与国际私募基金公司The Riverside Company达成了的合作协议，以支持其地区性和全球性的业务拓展，该合作使Avance Clinical的估值超过2亿澳元。首席执行官Yvonne表示，“有了具有国际合作经验以及在医疗健康领域有深度见解的Riverside的支持，Avance Clinical将通过收购的方式实现地区性以及全球性的扩展。”Avance Clinical是一家澳大利亚本土CRO公司，致力于为本地以及国际生物制药公司提供符合国际标准的临床研究服务，服务范围横跨各个临床研究阶段。同时，Avance Clinical也是一家被澳大利亚基因科技监管办公室（OGTR）认证的基因科技CRO，这使其有资格进行疫苗以及基因修饰生物体相关的临床研究。 首席执行官Yvonne谈到，“我们有着非常高的回头业务率，这足以证明我们的技术以及以客户为本的临床专家可以在快节奏和强竞争的环境中脱颖而出，满足我们客户的需求。”Avance Clinical在过去两年连续被Frost & Sullivan评为“CRO最佳实践奖 ”。更多信息：- 了解澳大利亚临床试验优势https://www.avancecro.com/the-australian-advantage/- 了解Avance Clinical在细胞和基因疗法领域的经验 www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/- 了解更多Avance Clinical执行临床试验的优势: enquiries@avancecro.com 关于Avance ClinicalAvance Clinical是澳大利亚和新西兰地区最大的一站式CRO公司。我们为客户提供高质量的临床研究服务以及符合国际标准的临床研究数据。我们的客户主要是处于早期研发阶段的生物科技公司，他们需要快捷灵活的临床研究服务。 Frost & Sullivan奖Avance Clinical作为一家具有24年历史的CRO公司在过去两年连续被评为Frost & Sullivan亚太地区市场领袖 。临床前到临床一期和二期Avance Clinical经验丰富的ClinicReady团队可提供精准的临床前服务。澳大利亚政府的研发税务补助政策，让我们可以更经济，精准并灵活的帮助客户完成临床一期和二期的项目。客户有机会享受43.5%的政府现金补助，同时快速的监管审批政策使其能更早更快的开展临床研究。我们的解决方案以及客户为本，灵活多变，经手的临床研究覆盖超过105个适应症。我们的数据质量被国际监管机构广泛认可，包括美国FDA以及欧洲EMA。技术我们使用的系统多元化并且功能丰富，有最高效的以及客户所信任的执行力。Medidata、Oracle和Medrio都是我们的系统长期供应商。媒体联系方式： Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization in APAC

ADELAIDE, AUS, Apr 19, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has been selected as a finalist for the Best Contract Research Organization in APAC by Informa Pharma Intelligence.Avance Clinical has undergone significant expansion in recent years, including new offices in Sydney and Melbourne to accommodate the growing clinical team in Australia.The award winner will be announced on 1 September 2022. The finalists are:- Avance Clinical- Calyx- CMIC Group- EPS- ICON- Parexel- Syneos HealthAvance Clinical's CEO Yvonne Lungershausen said:"Avance Clinical is extremely pleased to be selected as a finalist for this prestigious award. It is a credit to our amazing customer-focused team for delivering the CRO excellence that has been recognized by the Informa Pharma Intelligence award judges."Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients. We are very proud of our growth and success in APAC in recent years."According to Informa Pharma Intelligence:This Award is to recognize CROs that provide full or specialist services to their clients and which have an office in either in Japan or the Asia region including Australia.Judging considers the quality of services and relationships built with clients and pays particular attention to the innovative patient recruitment strategies the CRO has brought to the table.The award is based on achievements in the 2021 calendar year.Core areas judged include:- The particular capabilities and strengths the CRO offers- How the company has delivered results that exceed sponsor expectations- Innovations in patient recruitment strategy has the CRO brought to its partner- How it has improved its performance, for example, in its quality of data, timelines and transparency- The steps the company is taking towards streamlining data collection and reportingTo find out more please visit: https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m."With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions," said Lungershausen.Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies."We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Read more about Avance Clinical's cell and gene therapy capabilities here www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/- For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.com About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical墨尔本办公室正式启动

MELBOURNE, Mar 31, 2022 - (亚太商讯 via SEAPRWire.com) - Avance Clinical是澳大利亚本地最大的CRO，致力于协助世界各地的生物科技以及制药公司完成早期临床研究。目前，我们的墨尔本办公室已经正式启动，以协助大悉尼地区日益壮大的临床运营团队。所有墨尔本的员工，Avance管理团队以及董事会成员都参与了此次盛大的启动仪式。 Avance Clinical的首席执行官Yvonne Lungershausen表示：“一直以来，我们致力于为员工提供灵活的办公环境。但是，随着我们的员工和客户对于面对面交流需要的增加，我们决定为其提供一个优越的办公以及会议环境，同时为员工保留远程办公的选择。Avance墨尔本的办公室将支持持续扩大的墨尔本团队。”点击这里查看我们悉尼地区最新的招聘岗位。 https://www.avancecro.com/careers/ Avance Clinical最近与国际私募基金公司The Riverside Company达成了的合作协议，以支持其地区性和全球性的业务拓展，该合作使Avance Clinical的估值超过2亿澳元。首席执行官Yvonne表示，“有了具有国际合作经验以及在医疗健康领域有深度见解的Riverside的支持，Avance Clinical将通过收购的方式实现地区性以及全球性的扩展。”Avance Clinical是一家澳大利亚本土CRO公司，致力于为本地以及国际生物制药公司提供符合国际标准的临床研究服务，服务范围横跨各个临床研究阶段。同时，Avance Clinical也是一家被澳大利亚基因科技监管办公室（OGTR）认证的基因科技CRO，这使其有资格进行疫苗以及基因修饰生物体相关的临床研究。 首席执行官Yvonne谈到，“我们有着非常高的回头业务率，这足以证明我们的技术以及以客户为本的临床专家可以在快节奏和强竞争的环境中脱颖而出，满足我们客户的需求。”Avance Clinical在过去两年连续被Frost & Sullivan评为“CRO最佳实践奖 ”。了解澳大利亚临床试验优势：https://www.avancecro.com/the-australian-advantage/联系我们： https://www.avancecro.com/contact-us/关于Avance ClinicalAvance Clinical是澳大利亚和新西兰地区最大的一站式CRO公司。我们为客户提供高质量的临床研究服务以及符合国际标准的临床研究数据。我们的客户主要是处于早期研发阶段的生物科技公司，他们需要快捷灵活的临床研究服务。 Frost & Sullivan奖Avance Clinical作为一家具有24年历史的CRO公司在过去两年连续被评为Frost & Sullivan亚太地区市场领袖 。临床前到临床一期和二期Avance Clinical经验丰富的ClinicReady团队可提供精准的临床前服务。澳大利亚政府的研发税务补助政策，让我们可以更经济，精准并灵活的帮助客户完成临床一期和二期的项目。客户有机会享受43.5%的政府现金补助，同时快速的监管审批政策使其能更早更快的开展临床研究。我们的解决方案以及客户为本，灵活多变，经手的临床研究覆盖超过105个适应症。我们的数据质量被国际监管机构广泛认可，包括美国FDA以及欧洲EMA。技术我们使用的系统多元化并且功能丰富，有最高效的以及客户所信任的执行力。Medidata、Oracle和Medrio都是我们的系统长期供应商。媒体联系方式： Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Announces New Office Opening in Melbourne

MELBOURNE, Mar 31, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Melbourne to support its growing clinical team in the greater Melbourne region.The Avance Clinical team in MelbourneThe formal opening event was attended by all the Melbourne staff, as well the Avance Clinical executive team, and Board Members.Avance Clinical's CEO Yvonne Lungershausen said: "We continue to offer a hybrid working environment for our team however, they are increasingly wanting more in-office face-to-face time with colleagues and clients - while still having the flexibility of working remotely"."Avance is continuing to experience significant growth facilitating our expansion in the Melbourne CBD with new offices to accommodate our growing team," she said.Check for our latest positions open and join our Melbourne team here. https://www.avancecro.com/careers/ Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m."With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions," said Lungershausen.Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies."We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Learn about the Australian Advantage here. https://www.avancecro.com/the-australian-advantage/For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan awardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical悉尼办公室正式启动

SYDNEY, Mar 2, 2022 - (亚太商讯 via SEAPRWire.com) - Avance Clinical是澳大利亚本地最大的CRO，致力于协助世界各地的生物科技以及制药公司完成早期临床研究。目前，我们的悉尼办公室已经正式启动，以协助大悉尼地区日益壮大的临床运营团队。Avance Clinical的首席执行官Yvonne Lungershausen表示：“一直以来，我们致力于为员工提供灵活的办公环境。但是，随着我们的员工和客户对于面对面交流需要的增加，我们决定为其提供一个优越的办公以及会议环境，同时为员工保留远程办公的选择。Avance北悉尼的办公室将支持持续扩大的悉尼团队。”点击这里查看我们悉尼地区最新的招聘岗位 https://www.avancecro.com/careers/Avance Clinical最近与国际私募基金公司The Riverside Company达成了的合作协议，以支持其地区性和全球性的业务拓展，该合作使Avance Clinical的估值超过2亿澳元。首席执行官Yvonne表示，“有了具有国际合作经验以及在医疗健康领域有深度见解的Riverside的支持，Avance Clinical将通过扩张团队以及收购的方式实现地区性以及全球性的扩展。”Avance Clinical是一家澳大利亚本土CRO公司，致力于为本地以及国际生物制药公司提供符合国际标准的临床研究服务，服务范围横跨各个临床研究阶段。同时，Avance Clinical也是一家被澳大利亚基因科技监管办公室（OGTR）认证的基因科技CRO，这使其有资格进行疫苗以及基因修饰生物体相关的临床研究。 首席执行官Yvonne谈到，“我们有着非常高的回头业务率，这足以证明我们的技术以及以客户为本的临床专家可以在快节奏和强竞争的环境中脱颖而出，满足我们客户的需求。”Avance Clinical在过去两年连续被Frost & Sullivan评为“CRO最佳实践奖 ”。了解澳大利亚临床试验优势: https://www.avancecro.com/the-australian-advantage/联系我们: https://www.avancecro.com/contact-us/关于Avance ClinicalAvance Clinical是澳大利亚和新西兰地区最大的一站式CRO公司。我们为客户提供高质量的临床研究服务以及符合国际标准的临床研究数据。我们的客户主要是处于早期研发阶段的生物科技公司，他们需要快捷灵活的临床研究服务。 Frost & Sullivan奖Avance Clinical作为一家具有24年历史的CRO公司在过去两年连续被评为Frost & Sullivan亚太地区市场领袖 。临床前到临床一期和二期Avance Clinical经验丰富的ClinicReady团队可提供精准的临床前服务。澳大利亚政府的研发税务补助政策，让我们可以更经济，精准并灵活的帮助客户完成临床一期和二期的项目。客户有机会享受43.5%的政府现金补助，同时快速的监管审批政策使其能更早更快的开展临床研究。我们的解决方案以及客户为本，灵活多变，经手的临床研究覆盖超过105个适应症。我们的数据质量被国际监管机构广泛认可，包括美国FDA以及欧洲EMA。技术我们使用的系统多元化并且功能丰富，有最高效的以及客户所信任的执行力。Medidata、Oracle和Medrio都是我们的系统长期供应商。媒体联系方式： Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Announces New Office Opening in Sydney

SYDNEY, Mar 2, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region.Avance Clinical's CEO Yvonne Lungershausen said: "We continue to offer a hybrid working environment for our team however, they are increasingly wanting more in-office face-to-face time with colleagues and clients - while still having the flexibility of working remotely"."Avance is continuing to experience significant growth facilitating our expansion into North Sydney with new offices to accommodate our growing team," she said.Check for our latest positions open and join our Sydney team here. https://www.avancecro.com/careers/Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m."With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions," said Lungershausen.Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies."We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan awardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical在2022年生物技术展上宣布为美国扩张进行重大私募股权投资

ADELAIDE, AUS, Jan 19, 2022 - (亚太商讯 via SEAPRWire.com) - Avance Clinical 是澳大利亚最大的国际生物技术高级合同研究组织 (CRO)，已获得全球私募股权公司 Riverside Company (Riverside) 的重大投资，以支持进一步的区域和全球扩张。 该投资对公司的估值超过 2 亿美元。Avance Clinical 正在通过 PartneringOne 在2022 生物技术展上与生物技术公司举行会议，讨论在澳大利亚进行试验的好处，包括没有 IND 要求和有吸引力的 43.5% 回扣。在此处与 Avance 临床团队联系 https://www.avancecro.com/contact-us/ 在此处下载 Frost & Sullivan 的亚太地区临床试验优势报告 https://www.avancecro.com/download-apac-clinical-trial-report-frost-sullivan/ Avance Clinical 是澳大利亚拥有的 CRO，为本地和国际生物制药行业提供跨所有阶段的全球监管标准临床研究服务。该公司还被基因技术监管机构 (OGTR) 认可为基因技术 CRO，这使其能够扩展到疫苗和转基因疗法的临床试验。Avance Clinical 的首席执行官 Yvonne Lungershausen 表示：“在 Riverside 及其强大的全球影响力和深厚的医疗保健经验的支持下，Avance Clinical 将通过收购有机地执行其区域和国际扩张计划。”“我们已经证明，凭借我们的高增长和行业领先的重复业务率，我们对黄金标准技术的关注与以解决方案为导向的临床专家相结合，是我们的生物制药客户在这个快速发展、竞争激烈和高风险的行业所需要的组合， ” Lungershausen说。领先的分析公司 Frost & Sullivan 表示，亚太地区的 CRO 市场价值目前为 60.1 亿美元，预计到 2026 年将达到近 110.4 亿美元，复合年增长率为 12.2%。Avance Clinical 拥有 170 多名专业临床工作人员，并在过去两年连续荣获著名的 Frost & Sullivan CRO 最佳实践奖。Riverside 合伙人 Nick Speer 表示：“我们对 Avance 领先的管理团队非常感兴趣，他们已经获得了来自全球的蓝筹客户，为他们提供世界一流的服务。 Riverside 带来了数十年的全球生命科学经验，我们将利用这些经验进一步支持 Avance 的增长目标，特别关注北美和亚洲。”“澳大利亚是全球早期和越来越多的后期临床试验的首选目的地。我们打算与 Yvonne 和她的团队合作，进一步加快 Avance 的发展，”Speer 说。“全球赞助商都被澳大利亚和 Avance Clinical 所吸引，因为他们的试验质量和高效的时间框架。使用合适的 CRO，利用 IND 要求的缺乏和研发退税，可以在 5-6 周内完成研究启动。这意味着客户可以比世界上任何其他地方提前一年进入诊所，从而节省大量相关成本，同时使挽救生命的治疗更快地进入市场。”Avance Clinical 得到了 Allier Capital 的建议，而 Riverside 则得到了 Lazard Australia 的建议。在此处了解澳大利亚优势 https://www.avancecro.com/the-australian-advantage/有关在 Avance Clinical 开展下一项研究的好处的更多信息，请联系我们：https://www.avancecro.com/contact-us/关于 Avance Clinical www.avancecro.comAvance Clinical 是最大的优质全方位服务澳大利亚 CRO，在澳大利亚和新西兰为国际生物技术公司提供优质临床试验和全球公认的数据 24 年。我们的客户是处于药物开发早期阶段的国际生物技术公司，他们需要快速、敏捷和自适应解决方案导向的临床研究服务。Frost & Sullivan 奖过去两年获得 Frost & Sullivan 亚太 CRO 市场领导奖的 Avance Clinical 已在该地区提供 CRO 服务 24 年。临床前到第 1 和第 2 阶段Avance Clinical 凭借其经验丰富的 ClinicReady 团队提供临床前服务，直至 1 期和 2 期临床服务，利用高达 43.5% 的政府奖励回扣和快速启动监管流程。CRO 拥有超过 105 种适应症的经验，可以为 FDA 和 EMA 审查提供世界一流的结果和高质量的国际公认数据。技术作为一家公司，我们专注于跨所有职能领域的最先进技术和系统，为我们的客户提供最有效的流程。 Medidata、Oracle 和 Medrio 只是我们的部分技术合作伙伴。关于Riverside 公司Riverside 公司是一家全球私募股权公司，专注于投资价值高达 4 亿美元的成长型企业。 自 1988 年成立以来，Riverside 已进行了 800 多项投资。 该公司的国际私募股权和结构化资本投资组合包括 140 多家公司。媒体联络: Avance ClinicalChris Thompsonmedia@avancecro.comThe Riverside CompanyHolly Mueller hmueller@riversidecompany.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022

ADELAIDE, AUS, Jan 18, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m.Avance Clinical is taking meetings with biotechs to discuss the benefits of conducting trials in Australia, including no IND requirement and an attractive 43.5% rebate, at Biotech Showcase 2022 via PartneringOne.Connect with the Avance Clinical Team here https://www.avancecro.com/contact-us/Download the APAC clinical trial advantages report from Frost & Sullivan here https://www.avancecro.com/download-apac-clinical-trial-report-frost-sullivan/Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies.Avance Clinical's CEO Yvonne Lungershausen said: "With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions.""We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Leading analyst firm Frost & Sullivan says the Asia-Pacific's CRO market value, currently at $6.01 billion, is estimated to reach nearly $11.04 billion in 2026, growing at a compound annual rate of 12.2%.Avance Clinical has more than 170 specialist clinical staff and has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Riverside Partner Nick Speer said: "We were highly attracted to Avance's leading management team who have secured blue-chip customers from across the globe, providing them with world-class services. Riverside brings decades of global life sciences experience, which we will leverage to further support Avance's growth objectives, with a particular focus on North America and Asia.""Australia is the global destination of choice for early phase and increasingly later phase clinical trials. We intend to work with Yvonne and her team to further accelerate the growth of Avance," said Speer."Global sponsors are attracted to Australia and Avance Clinical for trial quality and efficient timeframes. Study start-up can be achieved in 5-6 weeks with the right CRO, leveraging the lack of IND requirement and the R&D tax rebate. This means clients can get into the clinic up to a year earlier than anywhere else in the world, saving significant associated costs while enabling life-saving treatments to reach market sooner."Avance Clinical was advised by Allier Capital and Riverside by Lazard Australia.Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan awardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.About The Riverside CompanyThe Riverside Company is a global private equity firm focused on investing in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has made more than 800 investments. The firm's international private equity and structured capital portfolios include more than 140 companies.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.comThe Riverside CompanyHolly Mueller hmueller@riversidecompany.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Client News: XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain

ADELAIDE, AUS, Oct 19, 2021 – (ACN Newswire) – Avance Clinical, the largest premium Australian CRO for international biotechs, is pleased to share the news that its client XWPharma Ltd. has announced dosing of subjects in its first-in-human study evaluating XW10508, the Company’s novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain. Avance Clinical is an award-winning Australian owned Contract Research Organisation (CRO) that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 24 years. Avance Clinical CEO Yvonne Lungershausen congratulated XWPharma saying: “Avance Clinical has an international reputation for expediting clinical trials in Australia which has an exceptionally supportive regulatory environment for biotechs”. “A key benefit for clients is that an IND is not required which means this is the fastest startup destination for international biotechs,” said Lungershausen. According to XWPharma: XW10508 is an oral, once-daily therapy and novel analog of esketamine, designed for improved tolerability, intended to provide prompt efficacy following initiation of treatment, and featuring potential abuse-deterrent properties. Phase 1 trial is a multi-part study in healthy subjects to assess safety, tolerability and pharmacokinetics of XW10508 in immediate release and modified release formulations at ascending doses. Over 264 million people worldwide suffer from major depressive disorders and roughly one-third of these patients are considered treatment-resistant, having failed two or more antidepressants. Additionally, one in five people worldwide experience chronic pain, while 8% of Americans suffer from chronic pain that frequently limits life or work activities. XW10508 is a new chemical entity derived from esketamine, designed for extended release, that is intended to deliver efficacy associated with esketamine in these populations without triggering the transient side effects that often accompany intranasal or intravenous administration. “We are pleased to be dosing subjects in this Phase 1 study of XW10508, as we continue to execute on multiple programs across our innovative CNS drug pipeline,” said Leonard Blum, President and CEO of XWPharma. “Despite available therapies for treatment-resistant depression and chronic pain, many patients are unable to find adequate relief. In the case of depression, standard of care therapy can require the patient to take four to eight weeks of therapy before noting benefits. There remains a glaring need for an agent that can provide a rapid response after the initiation of treatment, particularly for patients in crisis. The abuse potential and safety risks associated with many highly effective pain treatments also drive demand for new solutions.” The company’s Chief Medical Officer, Daniel Canafax, added, “Intravenous ketamine has been used with success in clinical practice for many years to treat depression and various pain states. The drug is given under physician supervision because of acute side effects including dissociation and sedation. Our vision is XW10508 will not produce these side effects by avoiding the high concentrations after IV ketamine while maintaining the drug exposure that produces antidepressant and analgesic effects.” The Company anticipates initial results from this study in early 2022, which will allow for rapid progression into a Phase 2a test of safety and efficacy in patient cohorts. For additional information about XWPharma, visit: www.xwpharma.com About XWPharma www.xwpharma.com XWPharma is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics, utilizing its proprietary platform chemistry. XWPharma’s expertise in drug design is focused on providing potential first- and best-in-class medicines with differentiated features to address the unmet medical needs of patients suffering from debilitating neurological diseases. William XiangStrategy & Operations | XWPharmaphone: +886 966 647 577email: william.xiang@xwpharma.com About Avance Clinical www.avancecro.com Avance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company’s clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. Frost & Sullivan awardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past 2 years, has been providing CRO services in the region for 24 years. Preclinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review. Avance Clinical delivers customised solutions designed around specific client needs rather than a one size fits all approach. TechnologyAs a company, Avance Clinical has focused on state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners. Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/ For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/ Media Contact:Chris Thompsonmedia@avancecro.com

Read More
Posted on

Avance Clinical临床试验合作申办方XWPharma正式开启其XW10508首次人类临床试验，研究快速缓解难治性抑郁症以及慢性疼痛疗法

ADELAIDE, AUS, Oct 19, 2021 - (亚太商讯 via SEAPRWire.com) - Avance Clinical的临床试验合作申办方XWPharma正式宣布其XW10508首次人类临床试验进入给药阶段。XW10508是一种谷氨酸能NMDA抑制剂和AMPA激活剂，作为一种治疗难治性抑郁症以及慢性疼痛的创新型口服药物，其给药剂量为每日一次。XWPharma已经为其注册专利。XW10508也是一种新型类艾氯胺酮药物，用于降低患者的耐药性以及增强目标适应症的疗效，同时降低患者滥用药物的可能性。此次的临床一期研究旨在评估XW10508速释型以及缓释加量型在健康受试者中的药物安全性，耐药性以及药代动力学结果。目前世界上有超过2.64亿人患抑郁症，其中大约三分之一的患者被诊断为难治性抑郁症，而且他们对至少两种抗抑郁药物都产生了抗药性。另外，目前全球有五分之一的人饱受慢性疼痛症的困扰。慢性疼痛症已经影响了8% 的美国人的正常工作和生活。XW10508是衍生于艾氯胺酮的新化学实体，作为一种缓释型药物，其优势就在于疗效高，同时避免了那些鼻内给药以及静脉注射类药物所产生的即时副作用。XWPharma公司主席兼首席执行官Leonard Blum说，很高兴我们的XW10508项目进入到给药阶段。而且，我们的中枢神经系统药物管线也有另外几个项目在同时进行。虽然针对难治性抑郁症以及慢性疼痛的药物不少，但是很多患者很难找到有效的缓解方式。对于抑郁症患者而言，标准疗法要求他们完成四到八周的疗程，在此之前是无法明确该疗法的有效性的。因此，对于“立刻见效”的药物的需求是非常明显的，尤其是对于那些重症患者而言。而且很多高效止痛药所带来的药物滥用以及药物安全性的潜在危害，也是我们寻求新疗法的动力。首席医学官Daniel Canafax补充说到，多年来，克他命静脉注射被用于临床上治疗抑郁症以及多种疼痛症状。然而，因为其强烈的镇静以及分解副作用，患者在使用克他命时需要医生的监护。我们XW10508的目标的就是通过避免高浓度的克他命静脉注射，去除这些副作用，同时保证药物在抗抑郁以及镇痛方面的疗效。XWPharma预测于2022年初拿到试验最初数据，之后会加速进行临床二期第一段的试验，测试XW10508针对患者的药物安全以及疗效。关于XWPharma www.xwpharma.comXWPharma是一家致力于新药发现以及研发的生物科技公司，我们的特长就是通过独特的药物设计，为那些饱受中枢神经系统类疾病困扰的患者提供创新以及最佳疗法，解决他们未被满足的临床需求。关于Avance Clinical www.avancecro.com Avance Clinical是澳大利亚以及新西兰地区最大的国际生物技术CRO，24年来一直为本地以及世界各国的制药以及生物科技公司提供符合全球监管标准的高质量临床研究服务。我们的客户多为需要灵活，便捷以及快速反应的早期药物研发类公司。Frost & Sullivan奖Avance Clinical在2019，2020年连续两年被Frost & Sullivan评为“亚太地区CRO市场领袖“。从临床前到临床一期/二期Avance Clinical经验丰富的ClinicReady团队可提供精准的临床前服务。澳大利亚政府的研发税务补助政策，让我们可以更经济，精准并灵活的帮助客户完成临床一期和二期的项目。客户有机会享受43.5%的政府现金补助，同时快速的监管审批政策使其能更早更快的开展临床研究。我们的解决方案以及客户为本，灵活多变，经手的临床研究覆盖超过105个适应症。我们的数据质量被国际监管机构广泛认可，包括美国FDA以及欧洲EMA。技术我们使用的系统多元化并且功能丰富，有最高效的以及客户所信任的执行力。Medidata、Oracle和Medrio都是我们的系统长期供应商。了解更多澳大利亚临床研究优势 https://www.avancecro.com/the-australian-advantage/ 联系我们 https://www.avancecro.com/contact-us/ Copyright 2021 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical 荣获 Frost & Sullivan 2021 年亚太地区 CRO 最佳实践奖，以表彰其客户价值领导力

ADELAIDE, AUS, Aug 11, 2021 - (亚太商讯 via SEAPRWire.com) - Avance Clinical 是澳大利亚最大的国际生物技术 CRO，荣获著名的 Frost & Sullivan 2021 亚太 CRO 客户价值领导奖，这是 Frost & Sullivan 连续第二次授予该公司亚太 (APAC) CRO 最佳实践奖。Avance Clinical 是一家澳大利亚拥有的合同研究组织 (CRO)，24 年来一直为本地和国际药物开发行业提供符合全球监管标准的高质量临床研究服务。Frost & Sullivan 表示，亚太地区的 CRO 市值目前为 60.1 亿美元，预计到 2026 年将达到近 110.4 亿美元，复合年增长率为 12.2%。“该地区正在成为首选的研发市场，中国、日本、澳大利亚和韩国处于领先地位，到 2020 年将占亚太地区临床 CRO 市场的 16%，”最佳实践的 Supriya Lala Kundu 表示Frost & Sullivan 研究分析师。这是 Avance Clinical 获得的第二个 Frost & Sullivan 奖项，该奖项在过去一年中在亚太地区取得了快速增长。Avance Clinical 的首席执行官 Yvonne Lungershausen 赞扬了她在澳大利亚和新西兰由 150 多名临床试验专家组成的团队。“我们已经证明，凭借 89% 的增长和超过 70% 的重复业务率，我们对黄金标准技术的关注与以解决方案为导向的临床专家相结合，是客户在这个快速发展、竞争激烈和高风险的行业中所需的组合。 Avance Clinical 对这一认可感到非常自豪。该奖项是对我们为客户提供价值的成功方法的真正认可。客户谈到澳大利亚对临床试验支出提供近 50% 的金融退税激励措施的优势——但我相信真正的好处是节省时间。我们的生物技术客户可以利用澳大利亚监管程序的快速启动并获得早期临床数据，而无需先获得其国内 IND。对我们的客户而言，最终效果是他们可以通过比世界其他任何地方提前一年进入诊所来加快他们的临床计划，并节省大量相关成本。 “Avance Clinical 专门支持生物技术公司的早期临床试验，在过去 5 年中进行了超过 195 项早期（第一和第二阶段）试验，涉及 105 个治疗适应症的 10,000 多名参与者。根据 Frost & Sullivan 最佳实践研究分析师 Supriya Lala Kundu 的说法：“自我们上次分析师审查以来，Avance Clinical 在过去一年中增长迅速，包括在澳大利亚和新西兰进一步扩展临床服务。其令人印象深刻的超过 70% 的重复业务率说明了其在该行业的客户价值和声誉，并且是 2021 年奖项选择的关键因素。Avance Clinical 的客户是主要来自美国、英国、日本、中国、韩国、台湾、法国和德国的国际生物技术公司。这些客户正在寻求具有与全球主要 CRO 相同的经验和先进技术平台的优质 CRO，但在澳大利亚和新西兰采用灵活且以客户为中心的临床管理方法。该公司提供来自 Oracle、Medidata 和 Medrio 等领先企业的一流技术，可实现全球所有主要监管机构都接受的快速高质量数据管理。由 150 多名临床专家组成的经验丰富的团队在超过 105 种适应症方面拥有丰富的经验。该公司被基因技术监管机构办公室 (OGTR) 认证为基因技术 CRO，使其能够扩展到疫苗和转基因疗法的临床试验。澳大利亚在符合 FDA 标准的卓越科学和研究、先进的医疗保健以及在临床试验竞争较少的环境中接触患者的机会进一步加强了其作为临床试验目的地的优势。”围绕 Avance Clinical 产品的主要 Frost & Sullivan 分析师发现包括：- 财务业绩：在收入、收入增长、营业利润率和其他关键财务指标方面实现了强劲的整体财务业绩- 客户获取：面向客户的流程支持高效、一致的新客户获取，同时提高客户保留率- 运营效率：公司员工高效、快速且高质量地执行分配的任务- 增长潜力：增长是由强烈的客户关注促进的，可以加强品牌并增强客户忠诚度- 人力资本：对质量和客户的承诺是公司文化的特征，这反过来又提高了员工的士气和保留率- 价格/性能价值：与类似的市场产品相比，产品或服务提供了最佳的价格价值- 客户购买体验：购买体验的质量向客户保证他们购买的解决方案是针对其独特需求和限制的最佳解决方案- 客户拥有体验：客户自豪地拥有公司的产品或服务，并在产品或服务的整个生命周期中获得积极的体验- 客户服务体验：客户服务触手可及、快捷、无压力、优质- 品牌资产：客户对品牌有积极的认知，并表现出较高的品牌忠诚度在此处了解澳大利亚优势 https://www.avancecro.com/the-australian-advantage/想了解更多关于在澳大利亚开展您下一项研究的优势，请联系我们：https://www.avancecro.com/contact-us/ 关于 Avance Clinical www.avancecro.comAvance Clinical 是最大的优质全方位服务澳大利亚 CRO，在澳大利亚和新西兰为国际生物技术公司提供优质临床试验和全球公认的数据 24 年。我们的客户是处于药物开发早期阶段的国际生物技术公司，他们需要快速、敏捷和自适应解决方案导向的临床研究服务。弗若斯特沙利文奖Avance Clinical 是 Frost & Sullivan 2020 年亚太 CRO 市场领导奖获得者和 2021 年亚太 CRO 客户价值领导奖获得者。临床前到第 1 和第 2 阶段Avance Clinical 凭借其经验丰富的 ClinicReady 团队提供临床前服务，直至 1 期和 2 期临床服务，利用高达 43.5% 的政府奖励回扣和快速启动监管流程。CRO 拥有超过 105 种适应症的经验，可以为 FDA 和 EMA 审查提供世界一流的结果和高质量的国际公认数据。Avance Clinical 提供围绕特定客户需求设计的定制解决方案，而不是一刀切的方法。技术作为一家公司，我们专注于跨所有职能领域的最先进技术和系统，为我们的客户提供最有效的流程。 Medidata、Oracle 和 Medrio 只是我们的部分技术合作伙伴。Media Contact: Chris Thompsonmedia@avancecro.com Copyright 2021 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

ADELAIDE, AUS, Jul 9, 2021 - (ACN Newswire via SEAPRWire.com) - The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial.Tetherex Pharmaceuticals, Inc. is a privately held, clinical stage biopharmaceutical company focused on development of selectin inhibitor therapeutics for the treatment of a broad range of inflammatory diseases and single-cycle adenovirus vaccines for multiple infectious diseases and cancer indications.Avance Clinical Chief Scientific Officer Dr Gabriel Kremmidiotis said:"The exciting aspect of the Tetherex product is the potential to vaccinate using a nasal spray. Administering the vaccine via the same route that the virus uses to get into our bodies, may result in more effective protection compared to the first generation Covid-19 vaccine products currently being administered as injectables. Commencement of dosing with the Tetherex Covid-19 vaccine product constitutes a major achievement for the Avance Clinical team who played a key role in supporting Tetherex in gaining regulatory approval to conduct the First-in-Human trial with their exciting vaccine candidate."According to Tetherex Pharmaceutical's announcement:Tetherex Pharmaceuticals has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform. The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19. Dosing of the initial cohort of the Phase 1 study is underway in Australia."Current adenovirus vaccines under investigation for COVID-19 and other infectious diseases are highly restricted in the amount of vaccine antigen they can deliver to cells," said Dr. Russell Rother, President and Chief Operating Officer of Tetherex. "The single-cycle adenovirus platform allows one round of robust vaccine antigen expression to occur without the generation of infectious virus particles which, in preclinical models, translates to a marked improvement in the ensuing immune response."About the Single Cycle Adenovirus Vaccine PlatformThe single-cycle adenovirus platform was developed to enhance the expression of target antigens, amplifying immune responses to infectious disease targets. Preclinical studies have demonstrated that the single-cycle adenovirus can increase target antigen expression up to 100-fold over currently utilized replication defective adenovirus vaccines. Intranasal administration of single-cycle vaccine elicits both systemic and mucosal immune responses. A mucosal response allows the immune system to encounter respiratory viruses like SARS-CoV-2 at the site of entry while the viral titers are lower. The platform also provides a robust manufacturing and supply chain paradigm relative to other vaccine platforms, such as mRNA.Tetherex's Phase 1 open label study, designed to assess safety, reactogenicity and immunogenicity of the single-cycle adenovirus vaccine, is expected to recruit a total of approximately 80 healthy volunteers and includes both a single ascending dose group and a multiple dose group. Subjects will receive the vaccine via either intramuscular or intranasal administration.The study site is Nucleus Network in Brisbane, and Dr Paul Griffin Nucleus Network's Principal Investigator said:"The covid 19 global pandemic continues to impact lives around the world. We are very fortunate to have developed a number of vaccines for Covid-19 already that are safe and highly effective. These vaccines are beginning to give us the capacity to start to reduce the impact of this viral infection, however it's clear there are certain properties of these vaccines that we would ideally like to improve upon such as having a vaccine that could be given via a route other than needle and syringe and perhaps a vaccine that could further reduce the ability for a vaccinated individual to become infected in the first place, a so called transmission blocking vaccine. A vaccine given intranasally has the potential to achieve some of these objects hence I am very excited to be the principal Investigator on the Tetherex clinical trial.""The addition of this novel vaccine platform to the Tetherex portfolio significantly expands our ability to leverage our scientific and clinical development expertise and broadens our overall technology base. This reduces risk to our investors while providing the potential of significant upside," said Dr. Scott Rollins, Chairman and Chief Executive Officer of Tetherex. "The platform will be utilized to target multiple infectious diseases which allows Tetherex to seek partnerships and alliances for the ever-expanding infectious disease marketplace."About Avance ClinicalAvance Clinical is the largest full-service Australian CRO focussed on delivering quality clinical trials in Australia and New Zealand for international biotechs. Avance Clinical has been delivering CRO services in the region for the past 24 years. Avance is accredited by the office of the gene technology regulator (OGTR) and has experience with the level of complexity involved in the granting of licenses from OGTR. This accreditation allows Avance to take responsibility, on behalf of clients, for the execution of trials which involve genetically modified organism products.The company's clients are international biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. Avance Clinical delivers customised solutions designed around specific client needs rather than a one size fits all approach. As a company Avance Clinical has focused on state-of-the-art technology and systems across all functional areas to provide clients with the most effective processes.Medidata, Oracle, and Medrio are just some of our technology partners. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of candidates who demonstrate passion and expertise in their chosen field. Visit http://www.avancecro.com for more information.Recent Awards:Excellence in Business Award 2021Frost & Sullivan Asia-Pacific CRO Market Leadership Award 2020Media Contact: media@avancecro.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More